Gi Innovation, Inc.
Clinical trials sponsored by Gi Innovation, Inc., explained in plain language.
-
New drug GI-108 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer. The trial has two parts: first, finding the safest dose, and then seeing if it shrinks tumors. Abo…
Phase: PHASE1, PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase: PHASE1, PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
Can a drug combo turn back the clock on aging? new trial begins
Disease control Recruiting nowThis early-stage study tests whether a combination of two experimental drugs, GI-102 and GIB-7, can improve immune function and other signs of aging in healthy adults and cancer survivors. The trial involves 15 participants and lasts 8 weeks, focusing on safety and changes in imm…
Phase: PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC